Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels J.P., Tao Y., Licitra L., Burtness B., Tahara M., Rischin D., Alves G., Lima IPF, Hughes BGM, Pointreau Y. et al., 2024/05. The Lancet. Oncology, 25 (5) pp. 572-587. Peer-reviewed.
ici le détail